Quantcast

Latest SQ109 Stories

2014-02-13 08:30:51

MOSCOW, February 13, 2014 /PRNewswire/ -- Russian and Korean biotech companies Infectex Ltd. [http://www.infectex.ru/?ln=en ] and Qurient Ltd. [http://maxwellbiotech.com ] have announced a license agreement granting Infectex exclusive rights to develop and commercialize Qurient's Tuberculosis-fighting drug Q203 in the Russian Federation, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan and Ukraine. (Logo:...

2009-11-16 08:37:00

Anti-Fungal, Additional Mycobacterial Indications Among Those Targeted ROCKVILLE, Md., Nov. 16 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat life-threatening infectious diseases, today announced that it amended an existing agreement with the National Institutes of Health (NIH) to significantly broaden the licensed therapeutic indications, or "field of use," for Sequella's lead drug candidate, SQ109. SQ109,...

2009-05-05 08:45:00

ROCKVILLE, Md., May 5 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today the start of its Phase 1B trial for SQ109 with the dosing of the first cohort of volunteers. SQ109, a new diamine antibiotic intended to replace one or more of the current first-line antitubercular drugs and simplify patient therapy, was granted U.S. FDA Fast Track designation and FDA/EMEA Orphan Drug Designation in 2007. SQ109 shows...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related